Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-087-2_6

Chapter 6: From Lab to Life: Safety, Regulatory Pathways and Clinical Trials in PCOS Nanomedicine

Tanuja[1], Harsh Goswami[2], Abhishek Tyagi[2], Sonal Sharma[2], Subhanshi Vishwas[3]

[1]I.T.S College of Pharmacy, Muradnagar, Ghaziabad, Uttar Pradesh, 201206, India.
[2]Raj Kumar Goel Institute of Technology (pharmacy), Ghaziabad, Uttar Pradesh, 201013, India.
[3]Department of Applied Science (Dep. of Chemistry), Invertis University, Bareilly, 243001, UP, India.

Corresponding Author*
Mr. Harsh Goswami
Email: harshgoswami0402@gmail.com, harshfph@rkgit.edu.in

Abstract

Polycystic Ovary Syndrome, commonly known as PCOS, is an intricate and multifaceted endocrine disorder that, in general, affects women at a reproductive age worldwide. Even though there have been some pharmacological advancements, the disorder still remains a challenge due to its complexities and heterogeneities which mostly lead to suboptimal clinical efficacy and the occurrence of negative side effects of the treatment. Consequently, treating PCOS with the resort of nanomedicine, which is nonetheless an attractive yet patient-friendly therapy of easy application, has been designed to treat PCOS. The present chapter charts out the whole transition of nanomedicine for PCOS starting with the bench-to-bedside innovation process. It discusses the preclinical safety testing of liposomes, polymeric nanoparticles, dendrimers, and nanogels that have been loaded with either plant-derived or synthetic drugs. There is also considerable attention given to preclinical toxicological assessment, and regulatory permission difficulties, as well as the standardization obstacles that could arise in the journey towards clinical validation. A comparative analysis of international regulatory bodies (FDA, EMA, and CDSCO) is intended to highlight the emerging guidelines and requirements of nanoformulations in the area of gynecological disorders. A comprehensive review of current and completed clinical trials indicates the extent of readiness for the PCOS nanomedicine to get into the mainstream. The future holds the promise of artificial intelligence (AI) based screening models, nano pharmacovigilance, and patient-centric delivery systems. The chapter is fully committed to conducting a thorough investigation while accompanied by four tables and three illustrations that provide a roadmap for researchers, clinicians, and regulatory scientists to make the nanomedicine innovation aimed at PCOS a reality.

Keywords: *Polycystic Ovary Syndrome (PCOS); Nanomedicine; Safety Evaluation; Toxicological Assessment; Regulatory Framework; Preclinical Studies; Clinical Trials; Good Manufacturing Practice (GMP); Pharmacovigilance; Translational Research; FDA and EMA Guidelines; Ethical Considerations*

1. INTRODUCTION TO PCOS

Polycystic Ovary Syndrome (PCOS) is a common, multifactorial endocrine disease that affects 6-15 percent of reproductive-aged women. It is diagnosed in cases of chronic anovulation, hyperandrogenic, and ovarian morphology that consists of numerous small follicular cysts. Symptoms slide into menstrual dysfunctions, infertility conditions, weight increase and obesity, hirsutism, acne, and even distortion of metabolic functions like insulin resistance and dyslipidemiaThe actual reason for the disease's occurrence is still unknown, although it is widely believed that polycystic ovary syndrome (PCOS) is the outcome of complex interplaying factors like genetics, hormones, environment, and lifestyle. PCOS, despite being one of the main causes of female infertility and the risk factor for type 2 diabetes and cardiovascular diseases, has not been adequately diagnosed and treated in many places around the world[1].

At present, PCOS treatment is mainly aimed at the symptoms, and the women can have regular periods, the androgen symptoms controlled, and their insulin resistance improved. The list of drugs regularly used includes oral contraceptives, anti-androgens (spironolactone), insulin sensitizers (metformin) and ovulation-inducing agents (clomiphene citrate). The classical drugs have worked but in some instances when patients develop serious side effects or become non-compliant or there is no safety confirmation for the long-term use and the drugs are incapable of addressing the multifactorial nature of PCOS's pathophysiology, loyalty to them is often hampers. Poor bioavailability and the absence of standard delivery systems still plague herbal and nutritional modalities, which are, by their nature, potentially beneficial[2].

The availability of recent evidence has triggered the research field of nanotechnology as a new form of therapeutic option in polycystic ovary syndrome (PCOS). Nanomedicine, nanotechnology in medical diagnoses and treatment, has a number of advantages compared to traditional drug delivery systems. The latter includes directed targeting to particular tissues, the increase in solubility and stability of poorly soluble substances, targeted release, and the ability to overcome Biological barriers. They can enhance the pharmacokinetics and the pharmacodynamics of drugs and phytoconstituents, reduce toxicity, and increase the effects in treatment. According to an increasing number of studies, the treatment of PCOS using liposomes, polymeric nanoparticles, solid lipid nanoparticles (SLN), dendrimers, and nanoemulsions as a method of delivering anti-androgenic agents, insulin sensitizers, and antioxidants proved successful[3]. Currently, nanomedicine in polycystic ovary syndrome (PCOS) is still at exploratory levels, and the body of evidence so far consists of both in vivo and in vitro measures. Still, the amount of efficacy data created so far has created the rationale of turning such knowledge into a medical practice. Transformation of lab research to treatment application involves strategic preclinical risk assessment, adherence to complex regulatory procedures, and formulation of rigorous clinical trials. Moreover, nanomedicines with their unique physicochemical properties bring about

issues of regulatory complexity, which subsequently necessitate the development of consistent guidelines and extensive quality-control regimes[4].

In this chapter, the authors strive to give a significant overview of the translational process of PCOS nanomedicine with the emphasis on the scientific, regulatory, and clinical aspects. It starts by discussing the category and modes of action of nanocarriers utilized in the treatment of PCOS and carries through with subsections addressing preclinical safety testing, regulations of varying countries, and the current state of clinically validated trials. This chapter intends to educate researchers, clinicians, and policymakers about the opportunities and challenges of nanotech-based interventions in the treatment of PCOS by plotting this so-called laboratory-to-life pathway[5].

2. NANOCARRIERS IN PCOS THERAPY: TYPES, MECHANISMS, AND APPLICATIONS

The advent of nanotechnology in medical practice has transformed into a mode of drug delivery, especially in multifactorial disorders such as Polycystic Ovary Syndrome (PCOS). Since PCOS is chronic in nature with hormonal imbalance and interlinked with insulin resistance, low-grade inflammation, and oxidative stress as its components, therapeutic intervention should cover multiple targets. Traditional medicines and phytopharmaceuticals, too, are not always sufficient because of their low bioavailability, side effects on the systemic level, and the absence of directed action. The use of nanocarriers is one of the possible ways to increase the effectiveness and safety of these interventions[6].

Liposomes are one of the first and most thoroughly investigated types of nanocarriers. These are vesicular systems that are made of phospholipid bilayers, and it has the potential to encase hydrophilic as well as hydrophobic drugs. Liposomes improve the solubility and stability of drugs and permit the release of drugs locally. Liposomal estradiol preparations have been shown to have potential in PCOS therapy as a direct deposition of hormones into the ovaries with less systemic hormonal fluctuations and adverse effects. They are biomimetic, therefore, are biocompatible, biodegradable, and non-toxic, so they could be used as long-term hormone regulators in PCOS.

Nanoparticles composed of polymers have also demonstrated great potential, in particular those made of biocompatible polymers, such as chitosan and poly(lactic-co-glycolic acid) (PLGA). Controlled and sustained release of therapeutic products through these carriers guarantees long-lasting activity and a decreased necessity for frequent administrations. Berberine is an alkaloid derived from plants that has insulin-sensitizing and anti-inflammatory effects, and it possesses low bioavailability when present in an oral form, and it has poor aqueous solubility. Berberine in the form of chitosan nanoparticles has a higher stability, intestinal absorption rate, and better therapeutic effects in PCOS animal models because it increases insulin sensitivity and decreases oxidative stress[7].

Lipids that are solid at room temperature and body temperatures form another generation of the colloidal drug carriers known as solid lipid Nanoparticles (SLNs). SLNs offer a drug encapsulation matrix enabling them to release drugs over a long time, and protecting the drugs against environmental degradation. Two polyphenols commonly employed in SLNs as a therapy against PCOS are resveratrol and curcumin, since they have a considerable antioxidant and anti-inflammatory effect. This showed their potential usage in humans, as they showed much-desired pharmacokinetics and enhanced histology of the ovaries in animal studies[8].

Dendrimers are tree-like nanostructures of high-order branching and consist of multiple terminal functional groups. This architecture supports multivalent loading of drugs and selective delivery. Dendrimer-based formulations of the aromatase inhibitor known as letrozole have been studied in PCOS. Through these systems, targeting can be made to the cells in the ovary, and the effect induced is better, fewer off-targets, and an increase in drug potency may be observed. Dendrimers can be considered as a suitable choice as a combination therapy in PCOS due to the property of inherent structural flexibility and surface modifiability[9]. Lipophilic drugs and herbal actives are compatible with nanoemulsions of kinetically stable oil and water blended by a surfactant. Conventionally, cinnamon oil, fenugreek extract, and Nigella sativa herbal compounds have been applied in the treatment of PCOS-related symptoms. They are, however, hindered by poor solubility and stability. Encapsulation in nanoemulsions has proved to be extremely effective in boosting their absorption capabilities and therapeutic effectiveness, particularly in the regulation of lipids, including androgens [10].

The mechanisms through which these nanocarriers enhance the treatment of PCOS are multifaceted. They guarantee targeted drug delivery to the ovaries, pancreas, adipose tissues, and liver- the ones involved in the pathophysiology of PCOS. Surface modification of nanoparticles can also make them recognize certain receptors overproduced in ovarian theca cells, hence being able to deposit drugs at a specific place. Also, nanoencapsulation shields the labile bioactives against enzymatic breakdown in the gastrointestinal tract by making a greater portion of the drug intact within the systemic circulation [11]. Pharmacodynamically, the systems facilitate the synergistic effect by providing medicines in a prolonged and controlled way. As an example, by integrating into the same nanoparticle antioxidants and insulin sensitizer, we might tackle at the same time metabolic dysfunction and oxidative stress in PCOS. Also, the capacity to penetrate biological obstacles and enhance intracellular uptake of therapeutic agents boosts the general efficacy of drugs. Nonetheless, there are still obstacles to transforming these nanocarrier systems to the bedside. Factors such as formulation scalability and regulatory approval, long-term biocompatibility, and economic feasibility are important variables that have to be considered. That said, preliminary studies have been continually reporting the beneficial effects of nanomedicine in enhancing the treatment of PCOS models, and this is a solid reason why such platforms can be developed into clinical handling [12].

3. PRECLINICAL SAFETY AND TOXICITY ASSESSMENTS IN PCOS NANOMEDICINE

The emergence of nanomedicine-based therapy in the PCOS requires strict preclinical safety and toxicity testing before it can be translated to the clinic. Given the peculiarities of physicochemical properties and the nanoscale size of nanocarriers, they can be characterized with individual biodistribution, pharmacokinetics, and even interactions with cells in contrast to commonly used drugs. That brings serious questions to their safety profile, setting up a massive in vitro as well as *in vivo* research to figure out the possible dangers of toxicological exposure[13].

At the preclinical level, in vitro tests are the initial method of evaluating cytotoxicity, the induction of oxidative stress, genotoxicity, or immunogenicity properties of nanocarriers. The common cells used in these tests are a cell line of human ovarian granulosa cells, hepatocytes, and epithelial cells whose model resembles the central targets involved in PCOS pathophysiology. As one example, the MTT assay is used to measure the activity of mitochondria as an indicator of cell viability, whereas reactive oxygen species (ROS) assays can be used to test whether the nanoparticles cause oxidative stress, which has been implicated in the pathology of PCOS. Nanoparticle-induced DNA damage can be checked by means of flow cytometry and comet assays so as to attain genomic safety. The systemic effects, biodistribution, and long term safety of nanoformulations require in vivo models, usually rodent prototypes of letrozole- or DHEA-induced PCOS. Such parameters as body weight, food consumption, organ weight indices, regularity of estrous cycle, hormonal profiles are observed. Histological examination is performed on organs like liver, kidney, spleen, lungs, ovaries and the brain in search of indications of inflammation, necrosis or fibrosis. Liver enzymes (ALT, AST), markers of kidney function (creatinine, BUN) and inflammatory cytokines (IL-6, TNF-a) are also measured, to detect organ-specific toxicity [14].

Toxicity outcomes are greatly affected by nanocarrier surface charge, size, shape, and composition. As an example, interaction with negatively charged cell membranes results in cationic nanoparticles being more cytotoxic in general, but the addition of PEGylation or surface functional groups using other natural polymers such as chitosan will enhance biocompatibility. Lipid carriers (e.g., liposomes and solid lipid nanoparticles) have positive safety profiles overall, and their biomimetic nature promotes good safety profiles when their lipid concentration and use of surfactants are optimized [15].

The other point to note is accumulation and clearance of nanoparticles in reproductive tissues. Given that PCOS influences the morphology and functioning of the ovaries, it is important to prove that nanoformulations are not able to disturb folliculogenesis and also hamper oocyte quality. Properly developed nanoparticles have been found to even re-establish ovarian structure in the form of histoarchitecture due to alleviation of oxidative stress and inflammations without toxicity.

Immunotoxicity also comes as a major concern since, some nanocarriers can activate complement responses or cytokine activation resulting in hypersensitivity or long-term immune response. Hence, immunocompatibility tests (including complement activation, cytokine profiling and immunoglobulin analysis) are vital during the safe formulation development [16]. To conclude, the preclinical safety and toxicity testing of PCOS nanomedicine must be multilevel using *in vitro* and *in vivo* small-scale experiments to assess the cytotoxicity, in vivo systemic studies or tests, and reproductive toxicity tests. The assessments are not only necessary in assuring that the nanoformulations are safe towards further formulation but it also helps in tuning formulation parameters towards maximum therapeutic advantage and less risk. Scrupulous preclinical testing is therefore an essential feature of responsible nanomedicine development in the treatment of PCOS [17].

4. REGULATORY PATHWAYS AND CHALLENGES FOR PCOS NANOMEDICINE

4.1. Global Regulatory Landscape: FDA, EMA, CDSCO, and WHO Guidelines

The regulatory framework for nanomedicine in the field of reproductive health and, at the same time, in the sphere of polycystic ovary syndrome (PCOS) is yet to crystalize under the influence of precision, safety, and efficacy. The United States Food and Drug Administration (FDA), European Medicines Agency (EMA), Central Drugs Standard Control Organization (CDSCO) India and World Health Organization (WHO) have all given frameworks, which though not disease-specific (PCOS) do provide all-encompassing guidance regarding nanotechnology-based therapeutics. Nanomedicines are controlled in the United States under the same laws as conventional drugs, but frequently need extra characterization to cover the nanoparticle-unique properties including particle size distribution, surface chemistry, zeta potential, and aggregation tendencies[18]. The FDA has published guidances such as the “Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology and Drug Products, Including Biological Products, that Contain Nanomaterials” that focus on making case-by-case determinations. EMA also works on the same principle although the organization has a dedicated Nanomedicines Working Party (NMWP) that reports and works on the Committee of Medicinal Products for Human Use (CHMP) to synchronize nanotechnology[19]. Aligned with the ICH, the CDSCO of India is nonetheless at the stage of incorporation of specific nanomedicine regulations, as it strongly relies on the available model of novel drug delivery systems (NDDS) and biosimilars. WHO as a global standards-setting organization has guidelines on quality, safety, and efficacy of nanomedicine, which may be considered to apply and to aid low- and middle-income countries in regulatoryAligning standard setting organization harmonization. In the case of PCOS nanomedicines, the challenge of meeting all these different yet interconnected regulatory standards necessitates that potential market penetration of its products, as well as international acceptance, occurs[20].

4.2. Classification of Nanomedicine Products in Reproductive Healthcare

Reproductive healthcare products of nanomedicine classification play a significant role in defining the regulatory process, dangerous classification, and the need of data. Nanomedicines may fit in many categories, including nanocarrier-based medication (liposomes, polymeric nanoparticles, dendrimers), nanotechnology-enabled diagnostics, and combination formulations of devices and drugs. In the case of PCOS, the effective treatment strategies mostly include hormonal drugs (e.g., nanoencapsulated metformin, nanoformulated clomiphene citrate) or phytoconstituents with anti-inflammatory characteristics (curcumin-loaded nanoparticles) or specific delivery of insulin sensitizers to the ovaries. Under the regulatory status, such products are mostly categorized according to their primary mode of action (PMOA)[21]. Assuming the product component of the PMOA is pharmacological, the product is treated like a drug; the intended use is mechanical, it may have medical device status; and in the situation that both components are of relevance, the product is treated as a combination product. FDA Combination products determination relies on 21 CFR Part 3; the EMA resorts to a case-by-case determination, under Directive 2001/83/EC. It also influences how much preclinical and clinical research is done- nanoformulations that dramatically change the bioavailability or biodistribution of an existing drug may have to be considered as new chemical entities (NCEs) and subjected to complete safety and efficacy testing. In the field of reproductive healthcare, the treatment involved is often a tradeoff between efficacy and reproductive safety, teratogenicity, and long-term effects of administration on the hormonal system, and hence the teratogenicity decisions play a direct role in study design and governmental regulatory review[22].

4.3. Requirements for Chemistry, Manufacturing, and Controls (CMC)

Nanomedicines impose a higher bar on any Chemistry, Manufacturing, and Controls (CMC) requirements because of the sophisticated interactions of the physicochemical properties with clinical performance. Regulatory bodies require comprehensive characterisation of critical quality attributes (CQAs) of particle size, morphology, polydispersity index (PDI), surface charge, drug loading efficiency and release kinetics. In the case of PCOS nanomedicines, this manufacturing process should also provide batch-to-batch reproducibility because differences in nanoparticle composition Hyphax can cause all necessary alterations in therapeutic efficacy and safety. There is an example of a change in the particle size of 80 to 150 nm as such a characteristic can affect ovarian tissue penetration and alter profiles of hormonal distribution[23]. The documentation that will accompany CMC will need to deal with raw material specifications, nanoparticle synthesis procedure, purification procedures, stability testing, and scalability. Regulatory authorities need powerful analytical tools- validated in line with ICH Q2(R2) to enable them to keep track of product quality across stages of its life. The Shelf life and storage requirements are key to establish through stability studies under ICH Q1A(R2) condition including accelerated and long term testing.

Moreover, an impurity profile needs to be provided in the case of reproductive health nanomedicines-relevant drug metabolites and degradation products (reproductive toxicology). The CMC section of a regulatory dossier is not only the basis of the product being approved but also a legal obligation of keeping the manufacture standards the same [24].

4.4. Pre-Investigational New Drug (Pre-IND) Consultations and Early Engagement

Regulatory interaction should be strongly encouraged early in the development of PCOS nanomedicines, since then the major roadblocks can be identified when not too much has been spent yet. Pre-IND Consultation Program The FDA Pre-IND consultation program provides sponsors with the ability to talk through their ideas of study design, manufacturing-related concerns, and regulatory expectations before applying to receive a formal request to put forward an IND. On the same note, the Scientific Advice procedure by the EMA and Pre-Submission meetings by the CDSCO would offer preliminary advice to direct product development to meet regulatory demands. In case of PCOS, such consultations may be especially useful in instances where the treatment method is based on innovative mechanisms, including deliberate distribution to the ovarian tissues or a dual approach to nanoformulations which combines the effect of hormonal control and metabolic modulations. The need to conduct reproductive toxicology studies; acceptability of the surrogates in terms of clinical endpoint; and the sufficiency of in vitro models, in the place of or to replace the animal model testing are some pressing issues that are likely to appear during the pre-IND discussions. There is also the possibility to talk about adaptive trial designs, bridging trials, and acceptability of foreign clinical data to domestic approval with early engagement. In addition, regulatory authorities are starting to promote patient-focused drug development (PFDD), practices where, in PCOS, they can include patient-reported outcome measures (PROMs) in trial design to more closely reflect symptom reduction and quality-of-life improvement[25].

4.5. Bridging the Gap: Device–Drug Combination Products in PCOS Care

The category of device-drug combination products constitutes a potentially thriving yet more complicated regulatory route of PCOS nanomedicines, once nanotechnology is embedded in the framework of an intrauterine device (IUD), microneedle patch, or vaginal rings to enhance the composition of hormones. These products have to meet regulatory requirements for both of drugs and the device. This may make it difficult to gain approval. In the United States, the Office of Combination Products (OCP) decides which will be the primary mode of action and which center will be the lead center-Center for Drug Evaluation and Research (CDER), Center for Devices and Radiological Health (CDRH), or Center for Biologics Evaluation and Research (CBER). The EMA and CDSCO are working based on common principles, yet operating differently in terms of the duration of procedures and dossier forms[26]. Device drug combinations, where available, might provide an advantage of long-term,

local therapy, which reduces the side effects systemically. Such products, however, will require extra biocompatibility study compared to ISO 10993, sterilization validation, leachables and extractables testing, and performance testing under relevant conditions during use. Another stability parameter that is specific to the nanoparticles incorporated in devices is the aggregation, due to ambient conditions, of nanoparticles in storage or the release of drug loading. Clearly, regulatory bodies will want to see the contribution that the device component will have with regard to therapeutic efficacy and safety, both in vitro release profiles and in vivo pharmacokinetics[27].

4.6. Regulatory Case Studies: Lessons from Approved Nanomedicines

The history of approvals of nanomedicines brings good lessons to the product development of PCOS focus. Indicatively, encapsulated nanoparticles have been proven more effective when it comes to the extent of lowered systemic toxicity and increased target specificity of drug delivery, as is the case with Doxil® (liposomal doxorubicin) - a principle that can be utilized with hormonal or metabolic compounds in PCOS. Abraxane (albumin-bound paclitaxel) made the necessity of avoiding toxic surfactants using an innovative nanocarrier much more visible, as safety margins are low in reproductive-age women. Nanoparticle Albumin-Bound (NAB) hormones showed great potential in the reproductive health space, as they improve bioavailability and decrease the dose, but the regulatory route was cautious, with broad reproductive toxicity data needed[28]. Among the lessons pertinent to nanomedicines is that more intensive post-marketing surveillance is needed; despite passing all regulatory hurdles, nanomedicines will continue to be monitored even after their post-marketing phases, as long-term safety signals might not have a chance to appear in the clinical trials. Approval of the Vyxeos 12 product (liposomal formulation of cytarabine/daunorubicin) in Europe also tells of the regulatory preference for not only clinical but additionally mechanistic explanation of the use of nanoparticles. In the case of PCOS, this means that evidence is needed of a tangible clinical benefit of the nanotechnology component over conventional formulations (in terms of improved ovulatory rates, metabolic control, or a decreased rate of adverse effects). Analyzing these precedents, the developers can learn how to foresee the regulatory issues, plan their development programs more structurally, and reduce the path toward market approval[2].

5. CHALLENGES IN REGULATORY APPROVAL

Regulatory approval of the use of nanomedicine-based treatment of polycystic ovary syndrome (PCOS) is in a distinct difficulty compared with other interdisciplinary research fields such as nanotechnology, reproductive endocrinology and pharmaceutical sciences. The lack of nanomedicine-specific rules on PCOS is one of the most urgent problems: although nanomedicine regulations are issued in certain jurisdictions, without any provisions connected to reproductive health, they are unlikely to help to work on gender-specific pharmacokinetics, safety, and long-term effects of the disease in women. The preclinical and clinical trials requirements are

affected by this regulatory gap causing ambiguity, which normally slows down the development schedules[22].

Inconsistency in the design of nanocarriers and scale-up issues also, make regulatory review more complex. Size, surface chemistry, functionalization, and payload can be substantially different in nanocarriers used to treat PCOS resulting in a high degree of variability associated with pharmacokinetics and biodistribution. Upscaling a lab scale production to industry scale production and preserving the correct physicochemical properties needed to induce the efficacy are both technically challenging, especially with complex biopolymers, lipid hybrids, and stimuli-responsive carriers. This kind of inconsistency impedes the regulators in setting standard measures of quality[29]. Reproducibility and batch-to-batch consistency is a closely related issue, Although at first glance the problem may not seem that pertinent to nanocarriers, the fact is that even small variations in synthesis processes, the quality of raw materials or even environmental conditions may change the performance profile of such a nanocarrier. Regulators pay a special attention to the uniformity of the products, though in case of nanomedicines, particularly in those ones that use biological substances, reproducibility on a high level is still a technological challenge. It frequently requires sophisticated methods of analysis of the particles and validation of their functionality, yet worldwide, these methods are not uniformly standardized in these disciplines.

There is an extra complexity that is brought by harmonization with international regulatory bodies. The U.S. FDA, the European Medicines Agency (EMA), as well as the agencies in Asia-Pacific regions frequently fail to be in harmony in terms of classification, risk assessment, and the requirements of approval of the nanoproducts. To the developers who want to achieve market access globally this implies replicating studies, modifying trial design, and fulfilling divergent documentation needs, hence pushing the cost and delaying commercialization[30]. Lastly, non-technical but very significant regulation challenges are ethical and societal concerns in women health nanomedicine. The fear among people about the potential risks that nanotechnology poses to fertility, pregnancy, and the well-being of their children can affect the choice of policies and priorities of funding. As well, issues of fair access, cost, and informed consent are of concern, especially in low, and middle-income countries with growing PCOS but with limited healthcare support. To handle these concerns, a clear process of risk benefit can be engaged, different population groups involved in trials and the creation of socially responsible commercialization must be made[1].

6. CLINICAL TRIALS IN PCOS NANOMEDICINE

The translational process of nanomedicine based interventions addressing issues of polycystic ovary syndrome (PCOS) preclinical stage to patient care necessitates well thought-out and painstakingly organized clinical trials. PCOS is a heterogeneous endocrine-metabolic disorder mainly observed in women of the productive age with hyperandrogenism, ovulatory disturbances, and polycystic morphology of the ovaries. It has a complex pathophysiology, which is frequently associated with insulin

resistance, chronic low-grade inflammation, dysregulated steroidogenesis, and aberrant folliculogenesis, posing special problems to clinical assessment. Nanomedicine can provide potential solutions to drug targeting, targeted release, improved bioavailability and decreased systemic toxicity of drugs to be used to treat PCOS. Nevertheless, the potential of nanocarriers and the multifactorial character of PCOS issue require certain modifications in the protocol of a clinical trial, inclusion of participants, choice of endpoint, and compliance with the regulations. It is covered in this part trial phases and proceedings including their adaptations as applied to nanomedicine, determining clinical endpoint, stratification of patient groups approaches, as well as biomarker-guided designs[31].

6.1 Trial Phases and Their Adaptations for Nanomedicine

The general approach to clinical trials of nanomedicine-based PCOS treatments is similar to classic Phases I-IV, although special accommodations must be made to address the physicochemical complexity of nanosystems; their different pharmacokinetics; and to enable more in-depth safety profiling.

- **Phase I: Safety and Dosage Optimization**
  Phase I trials in nanomedicine cannot only serve as a simple check of basic safety, but need to determine the nanoparticles-specific toxicity, biodistribution and immunogenicity of the material. In the case of PCOS applications, healthy female volunteers or women with mild hormonal dysregulation may be initially considered to be in the target population in order to reduce confounding comorbidities. Pharmacokinetic and pharmacodynamic characterization is more complicated than with traditional drug testing, because nanoparticles can cause nonlinear dose-response effects because of receptor saturation or opsonization/endosomal escape kinetics. They can be combined with more advanced imaging, e.g. dynamic contrast-enhanced MRI or PET, to depict the accumulation of nanoparticles in both the ovarian and peripheral tissues[32].
- **Phase II: Efficacy Assessment and Dose Refinement**
  Adaptive designs with provision to make dosing adjustments and stratify according to phenotype response tend to be suitable in PCOS nanomedicine Phase II trials. As the metabolic and hormonal background of PCOS phenotypes (A, B, C, D) differ, efficacy outcomes like recovery of ovulation or intensity of menstrual regularity, or the decrease in the level of androgens may also vary in applicability. There has also been attempts to include pharmacometric modeling in nanomedicine to predict optimum dosing regimes in situations where nanoparticles have long circulation times or stimuli responsive where pH, temperature or hormones gradually change[33].

- **Phase III: Large-Scale Validation**
  Phase III trials intended to confirm therapeutic efficacy and track long-term safety will consider a diverse population. In nanomedicine, the consistency and scale-up of

formulating nanoparticles are required because formulated products have the possibility of variability in terms of their therapeutic activity. Trials can be multicentric, considering ethnic differences in the manifestation of the disease, and ethnic variations may affect nanoparticle distribution and metabolic results. Also, combined outcomes can be used, which involve hormonal, metabolic, and reproductive indicators[34].

- **Phase IV: Post-Marketing Surveillance**
  The importance of post-marketing surveillance to the PCOS nanomedicines is especially important because of the chronic nature of drug usage and associated risks of chronic exposure with bioaccumulation, unanticipated reproductive effects, or metabolic changes attributable to nanoparticles. Registry-based and real-world data (RWD) analysis can become indispensable in detecting late adverse reactions or benefits, particularly on the aspects of pregnancy outcome, fertility restoration, and the prevention of metabolic syndrome[35].

6.2 Selection of Clinical Endpoints in PCOS Management

An integrated conceptualization of clinical endpoints in trials of PCOS nanomedicines is needed to encapsulate results in terms of reproductive outcomes, metabolic outcomes, and quality-of-life outcomes. In contrast to single-target diseases, PCOS presents itself in several physiological areas, which have requirements of endpoints with multiple dimensions[36,37].

- **Primary Endpoints**
  High priority is usually given to reproductive endpoints of ovulation induction rate, regularity of the menstrual cycle, intensity of follicular development (which is determined by ultrasonography), and pregnancy rate. Nanomedicine has the potential to improve these results by facilitating particular drug-delivery choices, such as delivering ovulation-stimulating drugs in a restricted region and the controlled discharge of insulin sensitizers or manipulation of the ovarian microenvironment.
- **Secondary Endpoints**
  The surrogate outcomes that can be used include the amendment of serum androgen status, hormone gonadotropin, (LH)/(FSH) ratio, anti-Mullerian hormone (AMH), and indices of insulin resistance (HOMA-IR, QUICKI). Also, metabolic outcomes (pathologies) like lipid profiles, fasting glucose, and inflammatory markers (e.g., CRP, IL-6) are vital, as the pathological effect that PCOS exposes individuals to is cardiometabolic.
- **Patient-Reported Outcomes (PROs)**
  Patient-oriented outcomes to be included are decrease in scores of hirsutism (modified Ferriman Gallwey score), severity of acne, weight loss and enhanced status of indices of mental health. Targeted action of nanomedicine would probably result in a quicker symptom relief, leading to higher patient satisfaction and compliance.

- **Surrogate Biomarkers**
  In nanoparticle-based therapies surrogate endpoints may be possible including decreasing stromal blood flow in the ovary (Doppler ultrasound) or normalization of certain blood metabolomic pattern, which have shown to correlate with far-term reproductive success.

6.3 Patient Recruitment and Stratification Based on Phenotypes

In PCOS nanomedicine, the recruitment should be based on the heterogeneity of syndrome. The stratification increases the strength of statistical analyses due to the minimization of variability and enables one to customize interventions[38,39].

- **Phenotypic Stratification**: The Rotterdam criteria define four main PCOS phenotypes:

  1. **Phenotype A**: Hyperandrogenism + Ovulatory Dysfunction + Polycystic Ovarian Morphology (PCOM)
  2. **Phenotype B**: Hyperandrogenism + Ovulatory Dysfunction
  3. **Phenotype C**: Hyperandrogenism + PCOM
  4. **Phenotype D**: Ovulatory Dysfunction + PCOM (non-hyperandrogenic)

- Nanomedicine molecules can possess phenotype specific efficacy. Examples include that insulin-sensitizing nanoparticles may help Phenotype A and B more since it is more dysregulated in metabolism and anti-androgenic nanocarriers may help Phenotype A and C because they are more dysregulated in androgens.
- **Genetic and Epigenetic Considerations**
  There can be a combination of genetic screening of androgen receptor genes, insulin receptor substrates, or gonadotropin-related genes as these could have an effect on the uptake of nanoparticles or therapeutic reaction. Stratification can also be based on epigenetic profiling, such as on DNA methylation profiles in ovarian tissue or peripheral blood.
- **Inclusion and Exclusion Criteria**
  In the case of women undergoing fertility, special considerations should be made because some aspects of nanomedicine cannot be considered safe during the early stages of pregnancy. On the other hand, severely affected patients with metabolic comorbidities may need to be excluded because of a change in nanoparticle pharmacokinetics.

6.4 Biomarker-Guided Trial Designs in Reproductive Nanomedicine

Biomarkers would make PCOS nanomedicine trials more precise since the effect of therapy on biomarkers can be assessed in real-time, or biomarker-driven go/no-go efficacy decisions in adaptive designs could be made early[40].

- **Hormonal Biomarkers**
  Monitoring of ovarian function and androgen excess requires AMH, total testosterone, free androgen index (FAI), and level of SHBG. Targeting of ovarian theca cells or granulosa cells with nanoparticle-based drug delivery, in particular, could normalize such parameters to an even greater extent compared with conventional drugs.
- **Metabolic Biomarkers**
  Early clues regarding metabolic advantages of nanomedicine interventions on the metabolism can be obtained with insulin sensitivity markers, adiponectin, leptin, and peculiar lipid metabolites. These markers may be used to adjust dosing by nanosystems conducting metformin or thiazolidinediones.
- **Inflammatory Biomarkers**
  In view of the importance of chronic inflammation in PCOS, TNF-α, IL-6, as well as MCP-1, can be used as indicators of efficacy. The measures could be used to follow anti-inflammatory nanocarriers like curcumin-loaded liposomes.
- **Nanoparticle-Specific Biomarkers**
  New imaging reporters or blood-stable nanoparticle detection assays can be added to the currently available tools to assess biodistribution and clearance, providing both safety benefits and clinical outcome correlation.

6.5 Case Examples of Nanomedicine Clinical Trials in Endocrine Disorders

Although we are only beginning to see dedicated nanomedicine trials of PCOS, there are several instances within related endocrine diseases that demonstrate the potential[41,42].

- **Metformin-Loaded Nanoparticles in Insulin Resistance**
  Phase II trials have been started on PLGA-based nanoparticles of metformin used in type 2 diabetes with an improvement in glycemic control and decrease in gastrointestinal issues. The results may be applicable to PCOS, in which insulin resistance is a fundamental pathophysiological driver.
- **LHRH-Targeted Nanocarriers in Ovarian Dysfunction**
  It has been assessed that nanocarriers conjugated by luteinizing hormone-releasing hormone (LHRH) peptides could be used to deliver therapeutic agents selectively to ovarian tissue in preclinical models. Preliminary safety results indicate little systemic toxicity.
- **Anti-Androgenic Nanoparticles in Hirsutism**

In hyperandrogenic disorders, liposomal forms of spironolactone and flutamide have been put to trial, where they demonstrated increased skin penetration and low level of systemic exposure, which is desirable in the case of PCOS-related hirsutism.

- **Curcumin Nanoparticles in Chronic Inflammation**
  The reduction of inflammatory cytokines and better lipid metabolism was proved in metabolic syndrome patients as a result of the administration of curcumin-loaded nanoparticles during a clinical trial. Such results are compatible with PCOS treatment objectives.
- **Vitamin D Nanoemulsions in Reproductive Health**
  Given the role of vitamin D in ovulation and insulin sensitivity, nanoemulsion-based supplements have been applied in vitamin D-deficient women, leading to better reproductive hormone profiles-A potential adjuvant role in PCOS is thereby discovered.

Table 6.1: Clinical Trials In PCOS Nanomedicine

Subsection	Focus Area	Key Details / Adaptations	Example(s)
Trial Phases and Their Adaptations for Nanomedicine	Preclinical to Phase IV adjustments	Preclinical encompasses developed advanced in-vitro models of PCOS and rodents with induced polycystic ovaries; Phase I involves safety and reproductive toxicology of the np, biodistribution and dose; Phase II/III allows adaptation dosing to different phases of the hormonal cycle; Post-marketing surveillance considers long-term endocrine effects	The Lipid -polymer hybrid nanoparticles with metformin that was used in Phase I evaluating whether it was reproductively inactive in animal models to take the next step into Phase II
Selection of Clinical Endpoints in PCOS Management	Efficacy and safety endpoints specific to reproductive nanomedicine	Primary outcomes: ovulation rate, regularity of menstruation, andro-gen levels decrease; Secondary: insulin sensitivity, weigh decrease, quality of life, ultrasound ovarian appearance; Nanomedicine specific safety outcome: nanoparticle clearance rate, oxidative stress	The effects of nano-curcumin in clinical trial carried out to improve menstrual cyclicity in patients with PCOS were gauged in terms of ovulation frequency and serum testosterone concentrations

		indicators	
Patient Recruitment and Stratification Based on Phenotypes	PCOS heterogeneity-based recruitment	Stratification by Rotterdam criteria phenotypes (A: hyperandrogenism + anovulation + PCO; B: hyperandrogenism + anovulation; C: hyperandrogenism + PCO; D: anovulation + PCO); Genetic profiling for susceptibility; Inclusion of lean vs obese PCOS variants to assess differential nanomedicine response	Phase II study with nanoparticle-based inositol formulation recruited both obese and lean PCOS groups to evaluate metabolic vs reproductive outcome differences
Biomarker-Guided Trial Designs in Reproductive Nanomedicine	Use of predictive, diagnostic, and monitoring biomarkers	LH/FSH ratio, AMH levels, HOMA-IR, fasting insulin, hs-CRP, IL-6, MDA, SOD; Biomarkers to help adjust the dose and control the response	The trial of nano-formulated resveratrol optimized dosing levels to enhance the most reproductive and metabolic beneficial effects of baseline AMH and fasting insulin levels
Case Examples of Nanomedicine Clinical Trials in Endocrine Disorders	Real-world nanomedicine applications in endocrine-related conditions	Clinical studies in diabetes, thyroid disorders, and infertility showcasing nanoparticle-based delivery of metformin, levothyroxine, or gonadotropins; Learnings applied to PCOS trials include improved bioavailability, targeted delivery to ovarian tissue, and reduced systemic side effects	In hypothyroidism, the nano-levothyroxine experiment produced prolonged release and maintenance of TSH control, which may be applied in the development of nanocarriers in hormone-modulating PCOS

7. FUTURE DIRECTIONS IN PCOS NANOMEDICINE TRANSLATION

Nanomedicine in polycystic ovary syndrome (PCOS) is soon to undergo a paradigm shift. In the last decade, nano-therapeutics and nano-diagnostics have been promising in singling out the multifactorial pathophysiology of PCOS through the spectrum of hormonal imbalance to chronic inflammation and insulin resistance. Nonetheless, despite promising early preclinical and pilot clinical research findings, translating such

innovations into routine clinical practice involves certain issues that need to be addressed using future-oriented strategies. Combined use of the latest digital technologies, including artificial intelligence (AI), a personalized approach to the concept of therapeutic constructs, novel and dynamic regulatory strategies, continuous safety monitoring based on digital health platforms, and global multi-center collaborative trial networks applied to women's health, will set the future course of PCOS nanomedicine translation. In combination, these developments have the potential to fill the gap between the innovations in the laboratory and patient-focused evidence-based care[26,33].

7.1. Integration of Artificial Intelligence in Regulatory and Safety Assessment

AI is finding its way to be a necessary partner in the nanomedicine regulatory and safety profiling. Regulatory scrutiny in PCOS therapy. The nature of the nanoparticles that might be used in his treatment (hormonally active nanocarriers, gene-editing-loaded nanoparticles, or metabolically active nanoparticles) should also ensure that regulatory review is not only comprehensive but adaptive. Conventionally, the regulatory authority uses uniform toxicology, pharmacokinetic modeling and clinical endpoints in a population. Nanomedicines, however, nanomedicines--and, in particular, endocrine-modulating nanomedicines offer more dynamic and challenging pharmacodynamics, necessitating more dynamic assessment techniques. New regulatory decision-making capabilities could use predictive toxicology models to anticipate nanoparticle interactions at both the molecular and systems level using in silico models. ML algorithms have the ability to analyze high-dimensional data sets generated in preclinical experiments (including nanoparticle surface chemistry, size distribution, charge, and release kinetics) and map to any potential adverse outcome [43].

In the context of PCOS nanomedicine, AI may be applied in order to develop early safety signals through mining of real-world evidence via electronic health records (EHRs) as well as wearable health trackers. Such AI-based systems would detect subtle patterns of adverse effects e.g., changes in menstrual cycle length, mild evidence of metabolic disturbance, and so forth, which would not be picked up in standard statistical analysis. Moreover, AI may help regulatory agencies with the adaptive licensing system according to which a conditioned approval will take place depending on the real-time monitoring of safety and efficacy and thereby bringing patients to the promising treatment without losing safety-related control. The development of the International Council for Harmonisation (ICH) guidelines with AI integration may facilitate the harmonization of the assessment of PCOS nanomedicines all over the world and help to ensure the pace of the developing nanotechnology does not outstrip regulatory science[44].

7.2. Personalized Nanomedicine for PCOS: Genomic and Proteomic Approaches

PCOS is found to be a very heterogeneous disorder, which is determined by genetics and common triggers in the environment and lifestyle. This diversity leads to the diversity in clinical phenotypes diversity- hyperandrogenism at the extreme end to metabolic syndrome- that may influence response to treatment. The second horizon of PCOS nanomedicine is the ability to use genomic and proteomic profiling to develop individualized treatment plans. The development of high-throughput sequencing and mass spectrometry has also enabled the discovery of genetic variation, transcriptomic and proteomic signatures relating to specific PCOS phenotypes. As an example, polymorphisms on the CYP17A1 gene, involved in androgen synthesis, or variation in the FTO gene to insulin sensitivity could be included in the stratification of patients. It is possible to design nanomedicines that would target molecular pathways relevant to the genomic and proteomic profile of an individual. This is possible because, as an illustration, the synthesis of siRNA-loaded nanoparticle concentration could be tailored to knockdown the overexpression of androgen receptor gene in hyperandrogenic phenotypes and anti-inflammatory nanoparticle formulation could target those with an elevated C-reactive protein level[45]. Proteomic information may inform the choice of ligand to provide tissue-specific delivery on nanoparticle functionalization surface of the theca cells of the ovary, adipose tissue, or the hypothalamic-pituitary axis. Nanomedicine design coupled with multi-omics analysis may revolutionize therapy effectiveness in terms of efficacy and off-target effects, which is of paramount importance in reproductive-age women. Moreover, future directions in personalized nanomedicine in PCOS will probably use a systems biology strategy, which combines metabolomics and microbiome characterization. Another newly-presented evidence implies that the composition of the gut microbiota modulates androgen metabolism, insulin resistance, and the tone of inflammation in the PCOS. It is therefore possible that formulations of nanomedicine products with prebiotic or probiotic agents, specific to an individual microbiome could become a new class of therapeutics. Precision nanomedicine and multi-omics will intersect so that PCOS management is based on disease-modifying rather than symptom-directed courses of action[46].

7.3. Novel Regulatory Frameworks for Next-Generation Nanocarriers

As PCOS nanomedicines progress beyond traditional liposomes and polymeric nanoparticles into the next generation of nanoparticle systems, including stimuli-responsive nanoparticle systems, hybrids (organic and inorganic), and multifunctional theranostic nanoparticles, regulations will also need to change. Adaptive nanomedicine technologies, which can be rapidly re-engineered, might not appeal to conventional drug approval processes, which can be slow, and they may follow a linear progression. Regulatory agencies are considering modular approval pathways, in which initial approval of a platform technology would be followed by regulatory review of changes that alter the active ingredient or the targeting ligand using an expedited review pathway. In case of PCOS-specific nanomedicines, a new framework should include

reproductive toxicology models and endocrine disruption to be used as a fundamental requirement. This is of special significance to nanocarriers that carry hormonal cargo or gene-editing elements which are delivered to the reproductive tissues[47]. The regulatory science also has to manage the lifecycle of nanomedicines, such as post-approval changes, scalability at the production stage, and long-term biocompatibility. Performance data in real life settings, captured using digital health systems, could be able to be incorporated into regulatory dossiers to facilitate a cycle of product design improvement. The international harmonization of rules and regulations will play a vital role in hastening the international availability of nanomedicines against PCOS. Joint efforts, like the International Pharmaceutical Regulators Programme (IPRP), may consider introducing PCOS nanomedicine case studies in their systems in order to harmonise PCOS safety and healing efficacy levels across borders. Also, by involving patient-reported outcomes in regulatory assessment, the approved nanomedicines will go beyond managing clinical outcomes to the quality of life measures as well, which are especially important in a multifactorial condition such as PCOS[48].

7.4. Role of Digital Health in Post-Market Surveillance

PCOS nanomedicines should be administered with close attention to their long-term effects on safety and efficiency once they are on the market due to the possibility of adverse reproductive, metabolic, or even psychological consequences of treatment. Digital health solutions such as wearable biosensors and smartphone apps serve as very useful real-time post-market surveillance tools. The platforms can monitor menstrual cycle, metabolic biomarkers (like continuous glucose monitoring data), sleep, and physical activity status, which gives an overview of the patient outcomes. AI analytics can also be integrated with it to identify anomalousities in the therapeutic response, and therefore, early intervention may be made to be administered. As an example, when a wearable device on a patient records a progressive rise in resting heart rate and interrupted sleep patterns, the system may indicate an adverse reaction as a possible case. Likewise, tracking menstrual apps would enable detection of shorter luteal periods or long menstrual cycles, which would produce alerts to the patient and the medical professional. Such a proactive pharmacovigilance not only contributes to the improved safety of patients but also gives researchers valuable real-world evidence that can be used down the road to support subsequent regulatory filings and product improvements. Patient engagement and adherence is also possible in DHP and this is important in chronic diseases such as PCOS. Health tracking that is gamified, telemetry coaching driven by AI, and safe telemedicine consultations can keep the patient motivated and guarantee no delays in following-up. Notably, data privacy and ethical matters should be considered and placed on the top of the list of issues because the information related to reproductive health is sensitive. Post-market surveillance using decentralised, patient-controlled data sharing through blockchain structured health records systems could be one of the solutions[49,50].

7.5. Multi-Center Collaborative Models for Women's Health Nanomedicine Trials

Historical clinical trials PCOS research has experienced limited representation in large-scale, multi-center trials, resulting in scattered evidence and limitedly generalized, a problem that necessitates improved study representation in multi center research. Nanomedicine translation in PCOS must focus on the paradigm shift-a network of multi-center trial collaborations that are directed to the study of women. These networks are resource groups, they can develop a common protocol and have a recruitment of diverse populations across the geographical, ethnic and socioeconomic background so that the results of the trial can be generalized. Multi-site partnerships are also best suited to quicken the enrollment of niche patient populations, eg adolescents with early-onset PCOS or post-menopausal women with residual metabolic complications. A harmonicized trial design may include adaptive strategies where interim data on efficacy and safety can be used to amend the trial during the trial itself, so an approach that can be used to accommodate very fast developing nanomedicine platforms. Additionally, translational research will be facilitated by shared biobanks and central repository of data allowing clinical outcomes to be linked with genomic, proteomic, and imaging data. International cooperation will be specifically useful in solving the regulatory and reimbursement issues. Multinational regulatory environments and joint trial designs that satisfy the needs of various regulatory agencies can simplify the approval process and enable cross-border access into novel PCOS therapy by lowering production cost and other necessities. Also, the collaboration among academic institutions, industry, and patient advocacy groups could guarantee compliance with the priorities of patient groups, such as fertility preservation, metabolic health, and increased quality of life[51-54].

CONCLUSION

PCOS or Polycystic Ovary Syndrome is an endocrine disorder that is complicated and multi-factorial and it occurs usually in women that are still in their reproductive age. The treatments currently available are not very effective and have safety issues as well. Nanomedicine is a new approach that is going to make things better by providing an effective, safe and precise drug delivery that controls the rate of release, thus, making it more available and also reducing the toxicity level in the body. A variety of nanocarrier systems including polymeric nanoparticles, lipid-based carriers, and hybrid nanosystems have shown supportive pre-clinical results in the areas of hormone equilibrium and metabolism restoration. On the other hand, the successful passage of PCOS nanomedicine needs to be supported by the standardization of safety evaluations, long-term toxicity profiling, and the establishment of regulatory frameworks that are in sync between FDA, EMA, and CDSCO. Large-scale clinical trials with clear outcomes and consideration of sex differences in pharmacokinetics are prerequisite in determining the efficacy of the treatment. In the future, the use of AI-enabled diagnosis, digital health innovations, and the merging of nanotherapy with nutraceuticals or hormonal agents for individualized treatment should be considered. The factors of making the treatment available, affordable, and reachable globally will be crucial for its real-world application. The combined use of nanotechnology, clinical pharmacology and systems medicine is the key that not only opens up the door for effective PCOS treatment but also for women's health improvement in the entire world.

Acknowledgement: Authors would like to thank Editors, Deep Science Publishers and Department of Pharmacy, Jagannath University to provide this opportunity.

Author Contribution: All authors have equal contributions in completion of this book chapter.

Funding: No funding.

Conflict of Interest: There is no conflict of interest.

REFERENCES

1. Lakshmi Narayanan P, Sugumar S, Rushendran R, Vellapandian C. Next-generation Approaches in Targeting Polycystic Ovarian Syndrome: Innovative Strategies. Curr Med Chem [Internet]. 2025 May 13 [cited 2025 Aug 14];32. Available from: https://www.benthamdirect.com/content/journals/cmc/10.2174/0109298673368951250404170052
2. Glendining KA, Campbell RE. Recent advances in emerging PCOS therapies. Curr Opin Pharmacol [Internet]. 2023 [cited 2025 Aug 14];68. Available from: https://www.sciencedirect.com/science/article/pii/S1471489222001722
3. Marinkovic-Radosevic J, Cigrovski Berkovic M, Kruezi E, Bilic-Curcic I, Mrzljak A. Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor. World J Diabetes [Internet]. 2021 [cited 2025 Aug 14];12(7):932–8. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8311482/
4. Mishra R, Kaur V, Nogai L, Bhandari M, Bajaj M, Pathak R, et al. Emerging Insights and Novel Therapeutics in Polycystic Ovary Syndrome. Biochem Cell Arch [Internet]. 2024 [cited 2025 Aug 14];24(2). Available from: https://search.ebscohost.com/login.aspx?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=09725075&AN=180711598&h=%2BXGvX0npbO7JeVHCmuqvAX2%2BIs8Nzfual5Bgm76Mp2aFFYWRyvdhp4YSSLieGoR%2FtYLT8Bgenz3XTUZ8fwlJjg%3D%3D&crl=c
5. Wawrzkiewicz-Jałowiecka A, Kowalczyk K, Trybek P, Jarosz T, Radosz P, Setlak M, et al. In search of new therapeutics-molecular aspects of the pcos pathophysiology: Genetics, hormones, metabolism and beyond. Int J Mol Sci [Internet]. 2020 [cited 2025 Aug 14];21(19):1–24. Available from: https://www.mdpi.com/1422-0067/21/19/7054
6. Shi M, Li X, Xing L, Li Z, Zhou S, Wang Z, et al. Polycystic Ovary Syndrome and the Potential for Nanomaterial-Based Drug Delivery in Therapy of This Disease. Pharmaceutics [Internet]. 2024 [cited 2025 Aug 14];16(12). Available from: https://www.mdpi.com/1999-4923/16/12/1556
7. Wang L, Mu L, Ye Y, Xu J, Zou X. Application of Fluorescent Composite Materials as a Sustained Release System in Treatment of Polycystic Ovary Syndrome. J Fluoresc [Internet]. 2024 Jul 1 [cited 2025 Aug 14]; Available from: https://link.springer.com/article/10.1007/s10895-024-03993-2
8. Fu Q, Fu L. Engineering nanosystems for regulating reproductive health in women. Theranostics [Internet]. 2025 [cited 2025 Aug 14];15(2):439–59. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11671389/
9. Muthukumaran D, Shanmugam R. Nanoparticle-based interventions for polycystic ovary syndrome: A review of mechanisms and therapeutic potential. J Drug Deliv Sci Technol [Internet]. 2024 [cited 2025 Aug 14];102. Available from: https://www.sciencedirect.com/science/article/pii/S1773224724010177
10. Raja MA, Maldonado M, Chen J, Zhong Y, Gu J. Development and evaluation of curcumin encapsulated self-assembled nanoparticles as potential remedial treatment for pcos in a female rat model. Int J Nanomedicine [Internet]. 2021 [cited 2025 Aug 14];16:6231–47. Available from: https://www.tandfonline.com/doi/abs/10.2147/IJN.S302161
11. Savithri Sateenapalli L, Krishna Professor Y, Kumar Mohanty Professor S. Development and Assessment of an Intravaginal Drug Delivery System for Polycystic Ovary Syndrome (PCOS). ajntmonline.com [Internet]. 2024 [cited 2025 Aug 14]; Available from: https://ajntmonline.com/wp-content/uploads/2025/04/V4-S3-7.pdf

12. Butt MA, Tabassum S, Hardy RS, Kiyani MM. Mechanistic insight into nanomedicine for polycystic ovary syndrome. Mol Biol Rep [Internet]. 2025 Dec 1 [cited 2025 Aug 14];52(1). Available from: https://link.springer.com/article/10.1007/s11033-025-10709-7

13. Lulseged BA, Ramaiyer MS, Michel R, Saad EE, Ozpolat B, Borahay MA. The Role of Nanomedicine in Benign Gynecologic Disorders. Molecules [Internet]. 2024 [cited 2025 Aug 14];29(9). Available from: https://www.mdpi.com/1420-3049/29/9/2095

14. Singh D. Nanotechnology-based Diagnostic Approaches for Early Detection and Monitoring of Polycystic Ovary Syndrome (PCOS). Curr Anal Chem [Internet]. 2025 [cited 2025 Aug 14];21(4):263–75. Available from: https://www.benthamdirect.com/content/journals/cac/10.2174/0115734110311450240612051821

15. Savithri Sateenapalli L, Krishna Professor Y, Kumar Mohanty Professor S. Development and Assessment of an Intravaginal Drug Delivery System for Polycystic Ovary Syndrome (PCOS). ajntmonline.com [Internet]. 2024 [cited 2025 Aug 14]; Available from: https://ajntmonline.com/wp-content/uploads/2025/04/V4-S3-7.pdf

16. Carter D, Better M, Abbasi S, Zulfiqar F, Shapiro R, Ensign LM. Nanomedicine for Maternal and Fetal Health. Small [Internet]. 2024 Oct 10 [cited 2025 Aug 14];20(41). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/smll.202303682

17. Butt MA, Tabassum S, Hardy RS, Kiyani MM. Mechanistic insight into nanomedicine for polycystic ovary syndrome. Mol Biol Rep [Internet]. 2025 Dec 1 [cited 2025 Aug 14];52(1). Available from: https://link.springer.com/article/10.1007/s11033-025-10709-7

18. Verma N, Arora S. Navigating the Global Regulatory Landscape for Exosome-Based Therapeutics: Challenges, Strategies, and Future Directions. Pharmaceutics [Internet]. 2025 [cited 2025 Aug 14];17(8):990. Available from: https://www.mdpi.com/1999-4923/17/8/990

19. Nandkumar M. Opinions in Medical Sciences, Technology and Health. OPINIONS IN Medical Sciences, Technology and Health [Internet]. 2024 [cited 2025 Aug 14];2(1 & 2). Available from: https://omsth.sctimst.ac.in/omsth/article/download/42/20

20. Singh D. Nanotechnology-based Diagnostic Approaches for Early Detection and Monitoring of Polycystic Ovary Syndrome (PCOS). Curr Anal Chem [Internet]. 2025 [cited 2025 Aug 14];21(4):263–75. Available from: https://www.benthamdirect.com/content/journals/cac/10.2174/0115734110311450240612051821

21. Fu Q, Fu L. Engineering nanosystems for regulating reproductive health in women. Theranostics [Internet]. 2025 [cited 2025 Aug 14];15(2):439–59. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11671389/

22. Acharya B, Behera A, Behera S, Moharana S. Recent Advances in Nanotechnology-Based Drug Delivery Systems for the Diagnosis and Treatment of Reproductive Disorders. ACS Appl Bio Mater [Internet]. 2024 Mar 18 [cited 2025 Aug 14];7(3):1336–61. Available from: https://pubs.acs.org/doi/abs/10.1021/acsabm.3c01064

23. Shaheen AA, Hussain KAM, Al-Safy AH. Preparation and characterization of nanocomposite from fresh green Asparagus Officinalis L. Stems and study of its biological efficacy in treating polycystic ovary syndrome induced by metformin suppository. Ginekologia i Poloznictwo [Internet]. 2024 [cited 2025 Aug 14];19(4). Available from: https://www.researchgate.net/profile/Alaa-Alsafy/publication/387762701_Preparation_and_Characterization_of_Nanocomposite_from_Fresh_Green_Asparagus_officinalis_L_stems_and_study_of_its_biological_efficacy_in_treating_Polycystic_Ovary_Syndrome_induced_by_M

24. Singh S, Arya V, Mishra RK, Rajput SK, Dhanasekaran M. Nanotechnology in the diagnosis and management of polycystic ovary syndrome: A systematic scoping analysis to improve patient care. Next Research [Internet]. 2024 [cited 2025 Aug 14];1(1):100004. Available from: https://www.sciencedirect.com/science/article/pii/S3050475924000046
25. Zheng CY, Yu YX, Bai X. Polycystic ovary syndrome and related inflammation in radiomics; relationship with patient outcome. Semin Cell Dev Biol [Internet]. 2024 [cited 2025 Aug 14];154:328–33. Available from: https://www.sciencedirect.com/science/article/pii/S1084952123000423
26. Hamed N, Soliman A, Beck C, Alaaraj N, Ahmed S, Alyafei F, et al. Bridging the gap: a comprehensive analysis of adolescent PCOS treatments and outcomes across decades. Endocrine Abstracts [Internet]. 2025 [cited 2025 Aug 14]; Available from: https://www.endocrine-abstracts.org/ea/0110/ea0110ep1018
27. Kumbhar PS, Chavan R, Darekar S, Kolekar K, Sequeira A, Vishwas S, et al. Bridging gap in treatment of polycystic ovarian syndrome through drug repurposing: what we achieved and where we are? Naunyn Schmiedebergs Arch Pharmacol [Internet]. 2025 Apr 1 [cited 2025 Aug 14];398(4):3213–40. Available from: https://link.springer.com/article/10.1007/s00210-024-03578-7
28. Davis EHS, Jones C, Coward K. Rethinking the application of nanoparticles in women's reproductive health and assisted reproduction. Nanomedicine [Internet]. 2024 [cited 2025 Aug 14];19(14):1231–51. Available from: https://www.tandfonline.com/doi/abs/10.2217/nnm-2023-0346
29. Raj M, Meena A, Seth R, Mathur A, Luqman S. An update on nanoformulations with FDA approved drugs for female reproductive cancer. J Microencapsul [Internet]. 2025 [cited 2025 Aug 14];42(3):266–99. Available from: https://www.tandfonline.com/doi/abs/10.1080/02652048.2025.2474457
30. Vijayakumar V, Rathinam T, Deenadhayalan SS, Edwin ER, Harikrishnan P, Balaji P. Nanoparticles in Hormonal Regulation of the Female Reproductive System. J BioX Res [Internet]. 2025 [cited 2025 Aug 14];8. Available from: https://mednexus.org/doi/abs/10.34133/jbioxresearch.0027
31. Butt MA, Tabassum S, Hardy RS, Kiyani MM. Mechanistic insight into nanomedicine for polycystic ovary syndrome. Mol Biol Rep [Internet]. 2025 Dec 1 [cited 2025 Aug 25];52(1). Available from: https://link.springer.com/article/10.1007/s11033-025-10709-7
32. Muthukumaran D, Shanmugam R. Nanoparticle-based interventions for polycystic ovary syndrome: A review of mechanisms and therapeutic potential. J Drug Deliv Sci Technol [Internet]. 2024 [cited 2025 Aug 25];102. Available from: https://www.sciencedirect.com/science/article/pii/S1773224724010177
33. Pal, R., Pandey, P., Chawra, H. S., & Singh, R. P. (2025). Niosomal as Potential Vesicular Drug Nano-carriers for the Treatment of Tuberculosis (TB). Nanoscience & Nanotechnology-Asia, 15(1), E22106812323829.
34. Shi M, Li X, Xing L, Li Z, Zhou S, Wang Z, et al. Prospects and Potential Applications of Nanomaterials in PCOS. 2024 [cited 2025 Aug 25]; Available from: https://www.preprints.org/frontend/manuscript/664707e7f36b0e6b98f161537fddc012/download_pub
35. Singh D. Nanotechnology-based Diagnostic Approaches for Early Detection and Monitoring of Polycystic Ovary Syndrome (PCOS). Curr Anal Chem [Internet]. 2025 [cited 2025 Aug 25];21(4):263–75. Available from: https://www.benthamdirect.com/content/journals/cac/10.2174/0115734110311450240612051821

36. Peng G, Yan Z, Liu Y, Li J, Ma J, Tong N, et al. The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis. Reproductive Biology and Endocrinology [Internet]. 2023 Dec 1 [cited 2025 Aug 25];21(1). Available from: https://link.springer.com/article/10.1186/s12958-023-01075-9

37. Pal, Rahul. (2025). Advancing Mitochondrial Health in Huntington Disease (HD): Small Molecule Therapies and Neurodegeneration. Current Aging Science. 10.2174/0118746098387655250818072130.

38. Lizneva D, Kirubakaran R, Mykhalchenko K, Suturina L, Chernukha G, Diamond MP, et al. Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. Fertil Steril [Internet]. 2016 [cited 2025 Aug 25];106(6):1510-1520.e2. Available from: https://www.sciencedirect.com/science/article/pii/S0015028216626663

39. Kiconco S, Mousa A, Azziz R, Enticott J, Suturina L V., Zhao X, et al. Pcos phenotype in unselected populations study (P-pup): Protocol for a systematic review and defining pcos diagnostic features with pooled individual participant data. Diagnostics [Internet]. 2021 [cited 2025 Aug 25];11(11). Available from: https://www.mdpi.com/2075-4418/11/11/1953

40. Mishra, R., Pal, R., Khan, Z., Sahoo, S., Chawra, H. S., & Kumar, D. (2025). Solid Lipid Nanoparticles (SLNPs): A State-of-the-Art Formulation Strategy and their Applications against Tuberculosis (TB) and Analgesic Effects. Nanoscience & Nanotechnology-Asia, 15(3), E22106812379362.

41. Abbasi M, Heath B, McGinness L. Advances in metformin-delivery systems for diabetes and obesity management. Wiley Online Library [Internet]. 2024 Sep 1 [cited 2025 Aug 27];26(9):3513–29. Available from: https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.15759

42. Kong T, Zong Y, Wang W, Su Z. Efficacy and Potential Molecular Mechanism of Metformin in Treating Cutaneous Disorders. authorea.com [Internet]. 2024 [cited 2025 Aug 27]; Available from: https://www.authorea.com/doi/full/10.22541/au.172007337.70305188

43. Pal, Rahul & Pandey, Prachi & Chawra, Himmat & Khan, Zuber. (2025). Nano Drug Delivery Carriers (Nanocarriers): A Promising Targeted Strategy in Tuberculosis and Pain Treatment. Pharmaceutical Nanotechnology. 13. 10.2174/0122117385367493250224103839.

44. Singh D. Nanotechnology-based Diagnostic Approaches for Early Detection and Monitoring of Polycystic Ovary Syndrome (PCOS). Curr Anal Chem [Internet]. 2025 [cited 2025 Aug 27];21(4):263–75. Available from: https://www.benthamdirect.com/content/journals/cac/10.2174/0115734110311450240612051821

45. Trisa Sunil A, Jo C, P. S. S, Kolasseri AE, Tamizhselvi R, Jayanthi S. Navigating the Future of PCOS Treatment: The Precision Medicine Paradigm. Curr Pharmacogenomics Person Med [Internet]. 2024 Aug 26 [cited 2025 Aug 27];21(2):58–68. Available from: https://www.benthamdirect.com/content/journals/cppm/10.2174/0118756921331801240820115132

46. Jaipal Reddy P, Jain R, Paik YK, Downey R, S. Ptolemy A, Ozdemir V, et al. Editorial (Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology). Curr Pharmacogenomics Person Med [Internet]. 2012 [cited 2025 Aug 27];9(3):159–67. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3264661/

47. Liu Y, Zhu J, Yang Y, Chen Z, Zhou Y, Fei W, et al. Extracellular matrix dysregulation in PCOS: pathogenesis, therapeutic strategies, and innovative technologies. J Biol Eng [Internet]. 2025

Dec 1 [cited 2025 Aug 27];19(1). Available from: https://jbioleng.biomedcentral.com/articles/10.1186/s13036-025-00533-9

48. Lakshmi Narayanan P, Sugumar S, Rushendran R, Vellapandian C. Next-generation Approaches in Targeting Polycystic Ovarian Syndrome: Innovative Strategies. Curr Med Chem [Internet]. 2025 May 13 [cited 2025 Aug 27];32. Available from: https://www.benthamdirect.com/content/journals/cmc/10.2174/0109298673368951250404170052

49. Usman US, Ahsan F, Alanjiro M, Bataba SY, Dallatu JA, Mahmood T, et al. The role of artificial intelligence in pharmacy: Revolutionizing drug development and beyond. Journal of Intelligent Medicine [Internet]. 2025 Jun 9 [cited 2025 Aug 27];2:27–43. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jim4.70003

50. Singh D. Nanotechnology-based Diagnostic Approaches for Early Detection and Monitoring of Polycystic Ovary Syndrome (PCOS). Curr Anal Chem [Internet]. 2025 [cited 2025 Aug 27];21(4):263–75. Available from: https://www.benthamdirect.com/content/journals/cac/10.2174/0115734110311450240612051821

51. Liu X, Bin C, Zhou Z, Zeng T, Wu K, Luo Y, et al. The neurobiology of plant-based therapeutics in women's reproductive health: mechanisms, efficacy, and clinical translation. Front Nutr [Internet]. 2025 [cited 2025 Aug 27];12. Available from: https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1591534/abstract

Rai, A., Shukla, S., Gupta, R. K., & Mishra, A. (2025). ALS: A Silent Slayer of Motor Neurons. Traditional Chinese Herbal Medicine as an Effective Therapy. *Current Pharmaceutical Design*, *31*(17), 1328–1346. https://doi.org/10.2174/0113816128329141241205063352

21. 53. Gupta, U., Kosey, S., & Pal, R. (2025). Advancements in nanotechnology-based targeted drug delivery systems for glioblastoma chemotherapy: A comprehensive review. *Journal of Drug Delivery Science and Technology*, *111*, 107181. https://doi.org/10.1016/j.jddst.2025.107181

22. 54. Pal, R., Pandey, P., Nogai, L., Arushi, Anand, A., Suthar, P., SahdevKeskar, M., & Kumar, V. (2023). THE FUTURE PERSPECTIVES AND NOVEL APPROACH ON GASTRO RETENTIVE DRUG DELIVERY SYSTEM (GRDDS) WITH CURRRENT STATE. *Journal of Population Therapeutics and Clinical Pharmacology*, *30*(17), 594-613. https://doi.org/10.53555/jptcp.v30i17.2852